Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Omega 3 pentaenoic acid · MAT-9001

Small molecule · developed by Matinas Biopharma

Phase 2 Most advanced trial (none active)
MTNB Developer
1 Registered trials

What is Omega 3 pentaenoic acid?

Omega-3 pentaenoic acid (MAT9001) is an encapsulated omega-3 fatty acid studied for hypertriglyceridemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MAT-9001
Drug type
Small molecule
Pathways
triglyceride synthesis
Therapy area
Metabolic
Developer
Matinas Biopharma, Inc (MTNB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
317SQ4W8IJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04177680 Phase 2 Hypertriglyceridemia Completed MTNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertriglyceridemia

More from Matinas Biopharma

Encochleated Amphotericin B Phase 3 MAT9001 Phase 3 Omega 3 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MTNB page.

Follow MTNB, the company behind Omega 3 pentaenoic acid

See MTNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MTNB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.